Investigation of the miRNA-mRNA Regulatory Circuits and Immune Signatures Associated with Bronchopulmonary Dysplasia

Sen Li1, Shuling Liang2, Shunyu Xie1

  • 1Guangzhou Women and Children's Medical Center, State Key Laboratory of Respiratory Disease and Guangzhou Medical University, Guangzhou, Guangdong Province, People's Republic of China.

PubMed
Abstract

Insights

MicroRNA-mRNA networks and immune cell changes are implicated in bronchopulmonary dysplasia (BPD). Reduced APP expression and activated neutrophils may drive BPD pathogenesis in preterm infants.

Area of Science:

  • Pulmonary Medicine
  • Genomics
  • Immunology

Background:

  • Bronchopulmonary dysplasia (BPD) is a significant cause of morbidity and mortality in preterm infants.
  • The underlying pathogenesis and mechanisms of BPD remain poorly understood.
  • This study investigates microRNA-mRNA regulatory networks and immune cell involvement in BPD.

Purpose of the Study:

  • To explore microRNA-mRNA regulatory networks in BPD.
  • To identify the role of immune cells in BPD pathogenesis.
  • To validate bioinformatic findings through experimental methods.

Main Methods:

  • Utilized Gene Expression Omnibus (GEO) datasets for microRNA and mRNA expression.
  • Predicted microRNA targets and performed protein-protein interaction analysis.
  • Screened hub genes and analyzed immune cell infiltration.
  • Validated findings using a mouse model with RT-PCR, IHC, and flow cytometry.

Main Results:

  • Identified two microRNAs (miR-15b-5p, miR-20a-5p) targeting genes in cell cycle and signaling pathways.
  • Found differential expression of APP and autophagy-related genes.
  • Observed significant differences in neutrophils and naive B cells in BPD patients.
  • Confirmed reduced APP expression and increased neutrophil activation in a BPD mouse model.

Conclusions:

  • Downregulation of APP, potentially mediated by miR-15b-5p and miR-20a-5p, may contribute to BPD development.
  • An increased CD62L-negative neutrophil subset could be crucial for immune-mediated injury in BPD.